Photodynamic Therapy Clinical Trial For Cutaneous AIDS-Related Kaposi's Sarcoma Study Summary.

Inclusion Criteria

Patients must have:

* Documentation of at least one biopsy-confirmed KS lesion.
* A minimum of 4 and no more than 36 KS lesions.
* All eligible lesions must be bidimensionally measurable, treatable by surface (non-contact) light illumination, and \<= 40 mm in diameter of the longest bidimensional axis.
* ACTG disease state T(0) L(0) or (1) S(0) or (1).
* Life expectancy greater than 6 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Active opportunistic infection or condition except thrush or herpes simplex virus infections.
* Advanced KS tumor stages including the presence of tumor associated edema or ulceration, extensive oral KS, or KS in other non-nodal viscera.
* Hematopoietic dysfunction.
* Coagulation dysfunction.
* Hepatic dysfunction.
* Renal dysfunction.
* Cardiovascular dysfunction - Presence of significant coronary artery disease requiring current treatment or myocardial infarction.
* Pulmonary dysfunction.
* Sepsis.
* Known disorder of lipoprotein metabolism or clearance.

Patients with the following prior conditions are excluded:

* History of allergic or hypersensitivity reactions to light, egg proteins or egg yolks, history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum.

Excluded within 7 days of therapy:

* Hematopoietic dysfunction.
* Coagulation dysfunction.
* Hepatic dysfunction.
* Renal dysfunction.

Excluded within 3 months of therapy:

* Pulmonary dysfunction.

Excluded within 6 months of therapy:

* Myocardial infarction.

Prior Medication:

Excluded:

* Intralesional chemotherapy within the past 12 weeks.
* Systemic chemotherapy or investigational drugs within the past 4 weeks.

Prior Treatment:

Excluded within 3 months prior to therapy:

* Local cryotherapy or surgery to study lesions.
* Systemic or topical photodynamic therapy agents.